Treatment of verruca vulgaris with topical cidofovir in an immunocompromised patient: a case report and review of the literature.
Lesions caused by verrucus vulgaris are commonly refractory to therapy and may become large, painful, or disfiguring in immunocompromised patients. Cidofovir is a potent nucleoside analog antiviral agent shown to have in vitro and in vivo activity against a broad spectrum of DNA viruses. We report a successful use of topical cidofovir to treat verruca vulgaris lesions in a highly immunocompromised patient, who was not considered a candidate for conventional therapy.
Cha
S
S
Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California 94305-5107, USA.
Johnston
L
L
Natkunam
Y
Y
Brown
J
J
D000287:Administration, Topical; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007866:Leg / Q000473:pathology; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage / Q000627:therapeutic use; D027383:Papillomaviridae / Q000187:drug effects; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome; D014860:Warts / Q000188:drug therapy* / Q000473:pathology / Q000821:virology
D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir